Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 clinical trials
Its developmentBy Sino Biopharmaceutical, step by step4 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQB2934 injection
- 3
Studies by the year they started
4 studies that test it; most in 2025 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934.
- Oct 2027A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsPhase 1 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07569757Written as TQB2934 injection
- Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsRecruitingPhase 1/2Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07266116Written as TQB2934 injection
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07179679Written as TQB2934 injection (subcutaneous injection)
- A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05646758Written as TQB2934 injection